Search results
Your search for ���������������,���������������������������������������:kn39��� returned no results
Showing 46 to 60 of 728 results for ���������������,���������������������������������������:know���
Showing 46 to 60 of 728 results for ���������������,���������������������������������������:know���
Dementia. Patient decision aid on enteral (tube) feeding for people living with severe dementia
people's weight or improved how well-nourished they were. It is not possible to know in advance what will happen to any individual...
Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)
Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.
Transition between inpatient mental health settings and community or care home settings (NG53)
This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.
This quality standard covers diagnosing and managing endometriosis in women and people, including those aged 17 and under. It describes high-quality care in priority areas for improvement.
We are listening to your views on this Health technology evaluation. Comments close 24 February 2026.
NICE content assurance service
receive email updates on interventional procedures guidance. We'll let you know when: you can comment on draft recommendations the final...
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
This quality standard covers managing acute painful episodes of sickle cell disease in hospital. It includes pain relief and care for children, young people and adults, from presentation in hospital until discharge. It describes high-quality care in priority areas for improvement.
View quality statements for QS58Show all sections
Sections for QS58
- Quality statements
- Quality statement 1: Timely assessment and analgesia
- Quality statement 2: Regular assessment of pain relief
- Quality statement 3: Strong opioids and monitoring
- Quality statement 4: Acute complications
- Quality statement 5: Protocols and specialist support
- Quality statement 6: Discharge information
- Update information
Learning disability: care and support of people growing older (QS187)
This quality standard covers identifying, assessing and regularly reviewing the care and support needs of people with a learning disability as they grow older. People with a learning disability have many of the same age-related health and social care needs as other people, but this quality standard focuses on the specific challenges associated with their learning disability. It describes high-quality care in priority areas for improvement.
View quality statements for QS187Show all sections
This quality standard covers diagnosing, assessing and managing cerebral palsy in children and young people under 25. It describes high-quality care in priority areas for improvement.
View quality statements for QS162Show all sections
Sections for QS162
- Quality statements
- Quality statement 1: Follow-up for children with major risk factors for cerebral palsy
- Quality statement 2: Referral for children with delayed motor milestones
- Quality statement 3: Information for parents and carers of children and young people with cerebral palsy
- Quality statement 4: Personal folders for children and young people with cerebral palsy
- About this quality standard
This quality standard covers preventing and identifying alcohol problems in the community. It includes policy and practice approaches to prevent harmful alcohol use in adults, young people and children. It is particularly relevant to local authorities, the police, and schools and colleges. It describes high-quality care in priority areas for improvement.
View quality statements for QS83Show all sections
Sections for QS83
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.